Zobrazeno 1 - 10
of 231
pro vyhledávání: '"F. Ambrosch"'
Publikováno v:
Infection. 32:149-152
This study was designed to assess the early antibody kinetics after a priming dose, and the extent of the antibody increase after a booster dose of an inactivated virosomal hepatitis A virus (HAV) vaccine (Epaxal®). This was an open, uncontrolled st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8e145f8d252c662d02bd47e102517d
https://doi.org/10.1007/s15010-004-3147-4
https://doi.org/10.1007/s15010-004-3147-4
Autor:
Gerhard Wiedermann, N. Garcon, F. Ambrosch, C. Thiriart, Moncef Mohamed SmithKline Beecham Bio. s.a Slaoui, Isabelle Desombere, Geert Leroux-Roels, M. Kundi, S Thoelen
Publikováno v:
Vaccine. 18:2095-2101
Although more than 95% of the vaccinated population responds to the currently licensed vaccines against hepatitis B, some groups were found to be low responders. Lipid A as adjuvant, through its ability to activate macrophages, might improve humoral
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb76a66b7a9e54b1e9f7b20d828e9dbe
https://doi.org/10.1016/s0264-410x(99)00566-6
https://doi.org/10.1016/s0264-410x(99)00566-6
Autor:
F. Ambrosch, David S. Fedson
Publikováno v:
PharmacoEconomics. 16:47-54
Objective: This report updates for 1996 and 1997 our 2 earlier reports on the use of influenza vaccination in various countries. Methods: Methods for obtaining information on influenza vaccine use from 1980 to 1995 in each country are described in ou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c903d6b6f774d9484ce52f521ca9b8
https://doi.org/10.2165/00019053-199916001-00007
https://doi.org/10.2165/00019053-199916001-00007
Autor:
Reinhard Glück, Gerhard Wiedermann, Christian Herzog, S. Jonas, B. Althaus, F. Ambrosch, Beatriz Finkel
Publikováno v:
Vaccine. 15:1209-1213
In this study we investigated a new liposomal hepatitis A vaccine (Epaxal) developed by the Swiss Serum and Vaccine Institute clinically and immunologically using a one dose priming schedule and a booster injection after 1 year. This vaccine contains
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6141f3cbd7d96345c6ac1bdcb51fc98f
https://doi.org/10.1016/s0264-410x(97)00015-7
https://doi.org/10.1016/s0264-410x(97)00015-7
Autor:
H. Gregor, Andrée Delem, E. D'Hondt, Francis E. André, F. Ambrosch, Hanns Hofmann, Gerhard Wiedermann, M. Kundi, Ch. Kunz, J. Wynen
Publikováno v:
Journal of Medical Virology. 44:452-456
As with hepatitis B vaccines, the recently developed hepatitis A vaccine is suitable not only for individual protection, but also for public health control measures. For introduction into routine immunisation programmes, however, hepatitis A vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b394ead6c3957b426bce895f242b4cb3
https://doi.org/10.1002/jmv.1890440426
https://doi.org/10.1002/jmv.1890440426
Autor:
H Bogaerts, Rudolphus Berger, H Vanura, Mp. Just, J. Wynen, D. Vandevoorde, Gerhard Wiedermann, F. Ambrosch
Publikováno v:
Vaccine. 12:210-214
Clinical and serological responses of infants to primary vaccination with diphtheria-tetanus-acellular pertussis (DTPa) vaccines containing 25 micrograms of filamentous haemagglutinin (FHA) and either 25 or 8 micrograms of pertussis toxoid (PT) were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de9c26d979f01e523849fdd949586182
https://doi.org/10.1016/0264-410x(94)90196-1
https://doi.org/10.1016/0264-410x(94)90196-1
Autor:
Gerhard Wiedermann, J. Gregor, L. Teulieres, Herwig Kollaritsch, F. Ambrosch, Susanna Jonas, B. Fritzell
Publikováno v:
Vaccine. 12:625-628
In order to evaluate a combination of yellow fever and typhoid fever vaccine, we conducted a controlled trial comparing reactogenicity and immunogenicity of Vi polysaccharide (ViPS) vaccine and yellow fever 17D (YF) vaccine after single, simultaneous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12a4158a7a41a205e91f68b20119a38f
https://doi.org/10.1016/0264-410x(94)90267-4
https://doi.org/10.1016/0264-410x(94)90267-4
Autor:
A. Delem, Ch. Kunz, Assad Safary, E. D'Hondt, F. Ambrosch, S. Jonas, Francis E. André, Gerhard Wiedermann
Publikováno v:
Vaccine. 10:S142-S145
Hepatitis A and hepatitis B are endemic in many countries and must be considered as serious health risks for large parts of the world population. Simultaneous or combined vaccination against these two diseases would therefore be most advantageous. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc4f7910d6feb6035719286389200a4e
https://doi.org/10.1016/0264-410x(92)90570-a
https://doi.org/10.1016/0264-410x(92)90570-a
Autor:
F, Ambrosch
Publikováno v:
MMW Fortschritte der Medizin. 146(25)
Diarrhea continues to be the most common cause of health problems encountered by travelers to tropical or subtropical countries. Every second traveler is affected. Since traveler's diarrhea cannot be reliably prevented by prophylactic measures, the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9cca934da36a9dc8673937d3a3943b4a
https://pubmed.ncbi.nlm.nih.gov/15354881
https://pubmed.ncbi.nlm.nih.gov/15354881
Publikováno v:
Acta tropica. 69(2)
The persistence of antibodies after a single dose and booster vaccination against hepatitis A (Havrix 1440) has not yet been assessed. By reanalysing previously published data of serum titres and application of a two-component model, we estimated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54b482337c7cb90c1dc397b9532c5b8a
https://pubmed.ncbi.nlm.nih.gov/9588232
https://pubmed.ncbi.nlm.nih.gov/9588232